Deviation and Nonconformance
Deviation management captures events, routes investigation, and documents disposition, with quality personnel determining classification and impact rather than the system.
Pharma quality management systems handle deviations, CAPA, change control, audits, supplier quality, and training records under GxP requirements. The system is itself inspected, so its validation, audit trails, and record integrity are examined alongside the quality processes it manages, and quality decisions remain with qualified personnel throughout.
An eQMS occupies an unusual position: it manages compliance while being subject to the same expectations it enforces. Taction Software builds pharma quality management software where the system’s own validation and data integrity meet the standard it exists to uphold, because an inspector examining a deviation record will also examine how the system holding it was qualified.

Our experts are ready to understand your business goals.






























































Pharma quality management software, commonly called eQMS, manages the quality processes GxP regulation requires: deviation and nonconformance handling, CAPA lifecycle from investigation through effectiveness verification, change control, internal and external audit management, supplier qualification, document control, and training record management. What distinguishes it from general workflow software is that its records are inspection evidence and its own qualification is subject to review. Our work sits within our broader pharma and life sciences practice.
Deviation management captures events, routes investigation, and documents disposition, with quality personnel determining classification and impact rather than the system.
CAPA workflow spans root cause investigation, action planning, implementation, and effectiveness verification, which is the step most frequently done poorly.
Change control manages proposed changes through impact assessment and approval, since unassessed changes to validated processes create compliance exposure.
Audit management handles planning, execution, findings, and response tracking for internal audits, supplier audits, and regulatory inspections.
Supplier qualification tracks approval status, audit history, and performance, since supplier failures propagate directly into product quality.
Training records link personnel qualification to documents and procedures, connecting with our data governance practice for controlled documentation.
Our pharma quality management software services cover eQMS development, process workflow, integration, validation, and inspection readiness. The design question we settle first is how much the system should enforce versus enable, because over-rigid workflow produces workarounds that undermine the quality system it was meant to strengthen. Engagements typically open with a review of current quality processes, inspection history, and where teams work outside the existing system.
We build quality workflow covering deviations, CAPA, and change control with the routing and approval structure your quality system defines.
Process design balances enforcement against usability, since workflow too rigid for real operations produces documented workarounds rather than compliance.
Integration spans manufacturing, laboratory, and regulatory systems, drawing on our enterprise application integration practice.
Quality events connect with broader risk processes, complementing our risk management software and incident reporting work.
Quality trending identifies recurring issues across deviations and complaints, supporting the periodic review GxP expects and inspections examine.
The eQMS is itself validated. Our 21 CFR Part 11 for AI work covers audit trails, signatures, and computer system validation.
The benefits concentrate in process visibility, cycle time on quality events, and inspection readiness. Deviation and CAPA backlogs are a common inspection finding, and backlog usually reflects workflow friction rather than insufficient effort. Trending across events also identifies systemic issues that individual investigations miss. We publish no figures on cycle time, backlog reduction, or inspection outcomes, because those depend entirely on your quality system maturity and manufacturing complexity.
Current deviation and CAPA status replaces the periodic manual reporting quality teams assemble for management review meetings.
Streamlined routing and approval reduces the delay between event and closure, addressing backlogs that draw inspection attention directly.
Structured effectiveness checks ensure CAPA closure includes verification, which is where quality systems most commonly fall short under review.
Trending across events surfaces recurring root causes that individual investigations treat as isolated, which is where real prevention originates.
Supplier qualification status and performance history inform sourcing decisions before quality problems propagate into product.
Complete audit trails and validation evidence support inspection as a maintained state rather than a preparation exercise before each audit.
We deliver pharma quality management software projects in gated phases so quality, manufacturing, and IT stakeholders approve direction before engineering cost accumulates. Discovery establishes current processes, inspection history, and where workarounds exist, since those indicate friction the new system must resolve rather than reproduce. Validation planning precedes development, because the eQMS is itself an inspected system and retrospective qualification is both expensive and weaker.
Discovery reviews current quality processes and identifies workarounds, since those reveal friction the new system must resolve rather than replicate.
We design workflow with quality personnel, balancing enforcement against usability so the system supports rather than obstructs real operations.
Validation scope is defined with quality assurance before development, since the eQMS is itself subject to inspection alongside the records it holds.
Development maintains traceability from requirement through test, accumulating validation evidence as a work product rather than a later exercise.
Validation follows IQ, OQ, PQ protocols with documented testing, traceability matrices, and change control appropriate to a GxP system.
Migration preserves historical records with integrity, followed by phased rollout with parallel operation where event continuity requires it.
Quality management systems operate under GxP requirements across good manufacturing, laboratory, and clinical practice, 21 CFR Part 11 for electronic records and signatures, and data integrity expectations summarized as ALCOA principles. Taction holds ISO 27001 certification. Two points deserve emphasis. The eQMS is itself an inspected system, so its validation is examined alongside its contents. And quality decisions including deviation classification and CAPA closure belong to qualified personnel, since these are judgments the regulation assigns to people.
Part 11 governs electronic records and signatures, requiring audit trails and validation for a system holding inspection evidence.
ALCOA expectations govern how records are created, changed, and retained, which shapes edit handling, versioning, and correction workflow technically.
Quality decisions including classification, impact assessment, and CAPA closure belong to qualified personnel rather than to workflow automation.
The eQMS is itself validated, since inspectors examine how the system holding quality records was qualified alongside the records themselves.
Retention requirements extend well beyond product lifecycle in some cases, so archival readability across system generations is designed deliberately.
Deployments run in your cloud tenancy or hybrid, with network segmentation, signed container images, and documented penetration testing before release.
Taction Software was founded in 2013 and has spent over 12 years building healthcare and life sciences software, delivering more than 200 healthcare projects from four US offices in Chicago, Cheyenne, Austin, and Sacramento, with ISO 27001 certification. Our relevant discipline here is designing workflow that people will actually follow. Quality systems fail through workarounds more often than through inadequate features, and a system nobody uses correctly is worse than a simpler one they do. Our leadership brings more than 20 years of personal experience in the field.
We identify existing workarounds during discovery, since they reveal where process friction will defeat any new system built without addressing it.
We produce validation evidence during development rather than retrospectively, since the eQMS is itself inspected alongside its records.
Founded in 2013, we have concentrated on healthcare and life sciences rather than treating them as one vertical among several.
Our work spans manufacturing, laboratory, and regulatory systems, which quality processes draw from across the organization.
We migrate historical quality records with integrity verification, since incomplete or altered event history is an inspection finding in itself.
ISO 27001 certification means security controls are documented and auditable, supporting client and inspection readiness efficiently.
Pharma quality management software pricing depends on scope, process count, integration breadth, migration volume, and validation depth. Validation is a substantial component since the eQMS is itself a GxP system, and we scope it separately so the share is visible. Most engagements involve configuration and extension of a platform rather than building an eQMS from scratch, which is rarely justified. Discovery produces an itemized, fixed-scope estimate. Platform licensing and cloud infrastructure are separate from engineering.
An MVP covering deviation and CAPA workflow typically runs $40,000 to $80,000 with proportionate validation documentation.
A full platform with deviations, CAPA, change control, audits, and training records typically falls between $80,000 and $200,000.
Enterprise engagements covering multi-site operations, supplier quality, migration, and full validation start at $200,000.
Discovery is a paid, time-boxed phase producing an itemized estimate, architecture plan, and validation scope reviewed with quality assurance.
Validation scope, process count, migration volume, and site count are the largest variables, identified during discovery for realistic budget planning.
Post-launch revalidation, process changes, regulatory updates, and support are quoted separately as a retainer sized to site and user count.
If you are evaluating pharma quality management software for deviations, CAPA, change control, audits, or training records, the fastest next step is a discovery call with our team. We will review current processes and workarounds, scope validation with your quality function, and return an itemized, fixed-scope estimate. Contact us to schedule that conversation.
Quality leaders evaluating pharma quality management software usually ask about validation burden, whether building is justified against commercial eQMS platforms, and how to avoid the workarounds that undermined their last system. The answers below reflect how we scope these projects.
Configure, almost always. Commercial eQMS platforms cover standard quality processes well and carry validation packages that reduce your burden. Building from scratch is rarely justified. Our work in this category is usually configuration, extension, integration, and validation support rather than ground-up development.
Because the eQMS is itself an inspected system, so its qualification is examined alongside the records it holds. That means documented IQ, OQ, and PQ with traceability and change control. Retrospective validation of a running system costs more and defends worse, so we plan it before development.
By identifying the ones that exist now and understanding why. Workarounds signal that the process as designed does not fit how work actually happens. A system that enforces an unworkable process produces documented non-compliance rather than compliance, so we design with quality staff rather than for them.
No. Closure requires effectiveness verification and qualified approval, which are judgments the regulation assigns to people. The system routes, documents, tracks deadlines, and prevents closure without required evidence. It does not determine whether a corrective action actually worked.
An MVP covering deviation and CAPA workflow runs $40,000 to $80,000. A full implementation typically falls between $80,000 and $200,000. Enterprise multi-site deployments with migration and full validation start at $200,000. Validation scope is the largest variable.
Yes, with integrity verification rather than bulk transfer. Historical deviation and CAPA records are inspection evidence, so altered or incomplete migration is itself a finding. We verify against source records and document the migration as a controlled activity with its own evidence.
Your email address will not be published. Required fields are marked *
Our expert reaches out shortly after receiving your request and analyzing your requirements.
If needed, we sign an NDA to protect your privacy.
We request additional information to better understand and analyze your project.
We schedule a call to discuss your project, goals. and priorities, and provide preliminary feedback.
If you're satisfied, we finalize the agreement and start your project.